Posted On: 11/10/2014 2:21:02 PM
Post# of 89467
RGLS Volume Alert - RGLS 24.09 Regulus Therapeutics Inc $RGLS Hit a high of 25.60 Currently 11:14 Last price 24.09 +2.01 +9.10% With a day low of 22.01 and a current volume of 1,998,722.
RGLS Regulus Therapeutics Inc Recent Headline News
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.39 (+0.94), ACHN: 12.62 (+2.51), RGLS: 22.43 (+0.35), ABBV: 63.57 (+2.07)
Regulus Therapeutics (RGLS) Strong On High Relative Volume Today
at The Street - Mon Nov 10, 9:04AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a strong on high relative volume candidate
RGLS: 22.43 (+0.35)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.67 (+0.47), GILD: 107.41 (+0.96), CNAT: 6.95 (+0.10), MRK: 58.84 (-0.50), LGND: 54.28 (+0.34), RGLS: 22.43 (+0.35), ABBV: 63.57 (+2.07), BMY: 58.49 (+0.17), ENTA: 43.87 (+0.54)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.67 (+0.47), GILD: 107.41 (+0.96), CNAT: 6.95 (+0.10), MRK: 58.84 (-0.50), LGND: 54.28 (+0.34), RGLS: 22.43 (+0.35), ABBV: 63.57 (+2.07), BMY: 58.49 (+0.17), ENTA: 43.87 (+0.54)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.67 (+0.47), GILD: 107.41 (+0.96), CNAT: 6.95 (+0.10), MRK: 58.84 (-0.50), LGND: 54.28 (+0.34), RGLS: 22.43 (+0.35), ABBV: 63.57 (+2.07), BMY: 58.49 (+0.17), ENTA: 43.87 (+0.54)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.67 (+0.47), GILD: 107.41 (+0.96), ACHN: 12.62 (+2.51), CNAT: 6.95 (+0.10), MRK: 58.84 (-0.50), LGND: 54.28 (+0.34), RGLS: 22.43 (+0.35), ABBV: 63.57 (+2.07), BMY: 58.49 (+0.17), ENTA: 43.87 (+0.54)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 325.47 (+4.72), ALNY: 98.54 (+2.70), ISIS: 46.69 (+2.10), OGXI: 2.16 (-0.02), TEVA: 58.15 (+0.45), RGLS: 22.43 (+0.35), GSK: 45.12 (+0.21), SNY: 46.26 (+0.57)
Regulus to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 10:30 a.m. MST. The conference is being held at the Arizona Biltmore in Phoenix, AZ.
RGLS: 22.43 (+0.35)
Insider Trading Alert - CBG, RGLS And WAB Traded By Insiders
at The Street - Thu Nov 06, 10:45AM CST
Stocks with insider trader activity include CBG, RGLS and WAB
CBG: 31.80 (-0.08), RGLS: 22.43 (+0.35), WAB: 89.49 (+0.22)
Regulus Therapeutics (RGLS) is in Overbought Territory: What's Next?
RGLS Regulus Therapeutics Inc Recent Headline News
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.39 (+0.94), ACHN: 12.62 (+2.51), RGLS: 22.43 (+0.35), ABBV: 63.57 (+2.07)
Regulus Therapeutics (RGLS) Strong On High Relative Volume Today
at The Street - Mon Nov 10, 9:04AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a strong on high relative volume candidate
RGLS: 22.43 (+0.35)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.67 (+0.47), GILD: 107.41 (+0.96), CNAT: 6.95 (+0.10), MRK: 58.84 (-0.50), LGND: 54.28 (+0.34), RGLS: 22.43 (+0.35), ABBV: 63.57 (+2.07), BMY: 58.49 (+0.17), ENTA: 43.87 (+0.54)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.67 (+0.47), GILD: 107.41 (+0.96), CNAT: 6.95 (+0.10), MRK: 58.84 (-0.50), LGND: 54.28 (+0.34), RGLS: 22.43 (+0.35), ABBV: 63.57 (+2.07), BMY: 58.49 (+0.17), ENTA: 43.87 (+0.54)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.67 (+0.47), GILD: 107.41 (+0.96), CNAT: 6.95 (+0.10), MRK: 58.84 (-0.50), LGND: 54.28 (+0.34), RGLS: 22.43 (+0.35), ABBV: 63.57 (+2.07), BMY: 58.49 (+0.17), ENTA: 43.87 (+0.54)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.67 (+0.47), GILD: 107.41 (+0.96), ACHN: 12.62 (+2.51), CNAT: 6.95 (+0.10), MRK: 58.84 (-0.50), LGND: 54.28 (+0.34), RGLS: 22.43 (+0.35), ABBV: 63.57 (+2.07), BMY: 58.49 (+0.17), ENTA: 43.87 (+0.54)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 325.47 (+4.72), ALNY: 98.54 (+2.70), ISIS: 46.69 (+2.10), OGXI: 2.16 (-0.02), TEVA: 58.15 (+0.45), RGLS: 22.43 (+0.35), GSK: 45.12 (+0.21), SNY: 46.26 (+0.57)
Regulus to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 10:30 a.m. MST. The conference is being held at the Arizona Biltmore in Phoenix, AZ.
RGLS: 22.43 (+0.35)
Insider Trading Alert - CBG, RGLS And WAB Traded By Insiders
at The Street - Thu Nov 06, 10:45AM CST
Stocks with insider trader activity include CBG, RGLS and WAB
CBG: 31.80 (-0.08), RGLS: 22.43 (+0.35), WAB: 89.49 (+0.22)
Regulus Therapeutics (RGLS) is in Overbought Territory: What's Next?
(0)
(0)
